Phase Ib Study of Chiauranib in Patients With Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2020-08-30
Target enrollment:
Participant gender:
Summary
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases
involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory
microenvironment.